Navco Pharmaceuticals Inc.
NAV.V
TSX
| Weiss Ratings | NAV.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Very Weak | |||
| Risk Grade | E+ | |||
| Reward Grade | E | |||
| Rating Factors | NAV.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Very Weak | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | NAV.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -- | |||
| Price History | NAV.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -50.00% | |||
| 30-Day Total Return | -50.00% | |||
| 60-Day Total Return | -75.00% | |||
| 90-Day Total Return | -80.00% | |||
| Year to Date Total Return | -66.67% | |||
| 1-Year Total Return | -85.71% | |||
| 2-Year Total Return | -- | |||
| 3-Year Total Return | -- | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -95.65% | |||
| 52-Week Low % Change | 0.00% | |||
| Price | NAV.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.12 | |||
| 52-Week Low Price | $0.01 | |||
| 52-Week Low Price (Date) | Jan 22, 2025 | |||
| 52-Week High Price (Date) | Jun 03, 2024 | |||
| Valuation | NAV.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 198.01K | |||
| Enterprise Value | 238.29K | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.02 | |||
| Earnings Per Share Growth | -43.29% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | -0.45 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.01 | |||
| Enterprise Value/EBITDA (TTM) | -0.37 | |||
| Enterprise Value/EBIT | -0.34 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | NAV.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 57.11M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | NAV.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | -- | |||
| Address | 5205 Harvester Road Burlington, ON L7L 6B5 | |||
| Website | navcopharma.com | |||
| Country | Canada | |||
| Year Founded | -- | |||
| Profitability | NAV.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | NAV.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -116.76% | |||
| Return on Equity | -- | |||
| Income Statement | NAV.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -638.30K | |||
| EBIT (TTM) | -695.40K | |||
| Net Income (TTM) | -1.27M | |||
| Net Income Avl. to Common (TTM) | -1.27M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -164.56% | |||
| EPS Diluted (TTM) | -0.02 | |||
| EPS Diluted Growth (Q YOY) | -145.75% | |||
| Balance Sheet | NAV.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 5.40K | |||
| Cash Per Share (Q) | $0.00 | |||
| Total Current Assets (Q) | 54.60K | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -634.20K | |||
| Current Ratio (Q) | 0.079 | |||
| Book Value Per Share (Q) | -$0.01 | |||
| Total Assets (Q) | 55.70K | |||
| Total Current Liabilities (Q) | 689.80K | |||
| Total Debt (Q) | 47.60K | |||
| Total Liabilities (Q) | 689.80K | |||
| Total Common Equity (Q) | -634.20K | |||
| Cash Flow | NAV.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -- | |||
| Cash from Financing (TTM) | 19.00K | |||
| Net Change in Cash (TTM) | -167.40K | |||
| Levered Free Cash Flow (TTM) | 455.50K | |||
| Cash from Operations (TTM) | -186.40K | |||
